AYTU BIOPHARMA, INC (AYTU) Form 10-K — Sep 22, 2026
Aytu BioPharma filed its FY2026 10-K reporting net revenue of $57.6 million and a net loss of $14.3 million, with $26.3 million in cash at June 30, 2026. EXXUA generated $6.6 million in its first year, but the legacy ADHD portfolio fell 20.4% to $45.8 million and the Pediatric portfolio fell 41.4% to $5.1 million as the sales force pivoted to the EXXUA launch. Generic competition is now live: Actavis/Teva launched its authorized generic of Adzenys in December 2025 and Teva's generic Cotempla entered July 1, 2026. Aytu is also litigating a Paragraph IV challenge from Granules over Adzenys, with trial set for January 12, 2027.
Key figures
- Revenue
- 57600000
- Total Debt
- $17.2 million outstanding under Eclipse Agreement as of June 30, 2026
- Cash Position
- 26300000
- Exxua net revenue
- $6.6 million (first year post-launch)
- Shares outstanding
- 10866708
- Accumulated deficit
- $347.8 million
- Prior year net loss
- $13.6 million (FY2025)
- Nols expiring unused
- $288.8 million by 2037
- Adhd portfolio revenue
- $45.8 million, down 20.4%
- Federal nol carryforwards
- $452.2 million
- Pediatric portfolio revenue
- $5.1 million, down 41.4%
- Eclipse term loan outstanding
- $11.1 million
- Eclipse revolving loan outstanding
- $6.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.